If you’ve been researching hormone therapy for menopause symptoms, you’ve probably encountered two very different narratives. One says hormone therapy is dangerous and should be avoided. The other says the fears are overblown and most women are undertreated. The truth — grounded in more than two decades of updated research — is more nuanced than either extreme. And understanding it could meaningfully change your quality of life.
This guide walks through what hormone therapy actually is, what the evidence says about its benefits and risks, and how to think through the decision for your own situation.
What Is Hormone Therapy for Menopause?
Hormone therapy (HT) — sometimes called menopausal hormone therapy (MHT) or hormone replacement therapy (HRT) — refers to the use of estrogen, alone or in combination with progestogen, to treat symptoms caused by the decline in hormone levels at menopause.
During menopause, estrogen production by the ovaries drops significantly. This drop is responsible for hot flashes, night sweats, vaginal dryness, sleep disruption, mood changes, bone loss, and more. Hormone therapy replaces enough estrogen to bring these symptoms under control.
There are two main types:
- Estrogen-only therapy (ET): Used by women who have had a hysterectomy (uterus removed) and do not need progestogen to protect the uterine lining.
- Combined estrogen-progestogen therapy (EPT): Used by women who still have a uterus. The progestogen component protects the uterine lining against the stimulating effects of estrogen alone, which could otherwise increase the risk of uterine cancer.
What Are the Benefits of Hormone Therapy?
Hormone therapy is one of the most studied treatments in women’s health. Here’s what the evidence shows it does well:
Relief from Hot Flashes and Night Sweats
Hormone therapy is the most effective treatment available for vasomotor symptoms — the hot flashes and night sweats that affect approximately 75 percent of menopausal women. For women with moderate-to-severe symptoms, it can be life-changing, dramatically improving sleep, energy, concentration, and day-to-day functioning.
Non-hormone alternatives exist and work for many women, but none match HT’s effectiveness for severe vasomotor symptoms.
Treatment of Vaginal and Urinary Symptoms
Estrogen deficiency causes the vaginal tissue to become thinner, drier, and less elastic — a condition called genitourinary syndrome of menopause (GSM). Hormone therapy, including low-dose local vaginal estrogen, relieves vaginal dryness, painful intercourse, and urinary symptoms like urgency and frequency. Importantly, low-dose vaginal estrogen delivers estrogen locally with minimal absorption into the bloodstream, making it an option for many women who are not candidates for systemic HT.
Bone Protection
Estrogen plays a critical role in maintaining bone density. Menopause accelerates bone loss — particularly in the first five to ten years — increasing the risk of osteoporosis and fractures. Hormone therapy effectively slows this process and reduces fracture risk. For women who also have bothersome symptoms and are at risk for bone loss, HT offers a dual benefit.
Mood and Cognitive Support
Many women report improved mood, reduced anxiety, and better mental clarity with hormone therapy. Research suggests that estrogen may be particularly effective at reducing depressive symptoms in perimenopausal women — even in those not experiencing hot flashes — though it has not been approved by the FDA specifically for mood disorders.
Potential Cardiovascular Benefit (Timing Matters)
This is one of the more nuanced areas. When HT is started in women younger than 60 or within 10 years of menopause, some studies suggest a potential protective effect on the heart. This is sometimes called the “timing hypothesis” or the “window of opportunity.” However, HT started much later — in women over 65 who are more than a decade past menopause — may carry a slightly increased cardiovascular risk. This is why the timing and individualization of HT decisions matter enormously.
What Are the Risks of Hormone Therapy?
The fears around hormone therapy largely trace back to a 2002 study from the Women’s Health Initiative (WHI), which reported increased risks of breast cancer, heart disease, stroke, and blood clots. The subsequent alarm caused a dramatic drop in HT prescriptions — and left many women undertreated for years.
Since then, that study has been extensively reanalyzed and its findings recontextualized. Here’s a more accurate picture of the risks:
Breast Cancer
The most frequently discussed concern. Combined estrogen-progestogen therapy is associated with a small increase in breast cancer risk with use beyond four to five years. To put it in perspective: the absolute increase in risk is small — comparable to, or less than, the risk associated with drinking one alcoholic beverage per day or being sedentary. Estrogen-only therapy (for women without a uterus) does not appear to carry the same risk and may actually be associated with a slightly lower breast cancer risk.
The type of progestogen used may matter. Micronized progesterone (bioidentical progesterone, such as Prometrium) is associated with a more favorable risk profile than synthetic progestins in some studies — an important consideration when making treatment decisions.
Blood Clots and Stroke
Oral (pill-form) hormone therapy is associated with a slightly elevated risk of blood clots in the legs or lungs (venous thromboembolism) and stroke. However, transdermal forms — patches, gels, creams, and sprays — appear to carry significantly lower or no increased risk of blood clots. This is because transdermal estrogen bypasses the liver (the first-pass effect), avoiding the clotting factor changes associated with oral estrogen.
Dementia
If HT is started in women aged 65 or older, there is evidence of increased dementia risk. This is part of why starting HT during the natural transition window — in your 40s or 50s, close to menopause onset — is generally considered much safer than initiating it decades later.
Who Is a Good Candidate for Hormone Therapy?
According to current evidence and guidance from The Menopause Society, most healthy women under 60, or within 10 years of menopause, with bothersome symptoms are appropriate candidates for hormone therapy — and the benefits generally outweigh the risks for this group.
HT may not be appropriate for women with:
- A personal history of estrogen-receptor-positive breast cancer (though even this is evolving, particularly for local vaginal estrogen)
- Active or recent blood clots or stroke
- Active cardiovascular disease
- Unexplained vaginal bleeding
- Certain liver conditions
This is exactly why a thorough, individualized evaluation matters. A blanket “HT is too dangerous” position is not supported by current evidence — but neither is a one-size-fits-all prescription. The right answer depends on your symptoms, your health history, and your priorities.
Hormone Therapy Delivery Options: More Than Just a Pill
One of the most important advances in hormone therapy is the variety of delivery methods now available. The form you choose can significantly affect both your experience and your risk profile.
Patches are applied to the skin and changed one to two times per week. Transdermal delivery bypasses liver metabolism and is associated with lower clotting risk than oral estrogen.
Gels and creams are applied daily to the arm, shoulder, or thigh. They offer flexible dosing and the same transdermal benefits as patches.
Sprays deliver a metered dose of estradiol to the forearm — a convenient option for women who prefer not to wear a patch.
Pills are the most familiar form but carry slightly higher clotting risk due to first-pass liver metabolism. They may still be appropriate for some women.
Vaginal rings deliver either systemic or local estrogen depending on the dose. The low-dose vaginal ring (Estring) works locally for GSM; the higher-dose ring (Femring) provides systemic benefit for hot flashes.
Vaginal estrogen (cream, suppository, tablet, or ring) delivers estrogen directly to vaginal tissue with minimal systemic absorption. It is effective for GSM and is considered safe for most women, including many cancer survivors.
How to Decide: A Framework for the Conversation
The decision about hormone therapy is not one you need to make alone — or make based on fear. Here are the key questions to bring to your provider:
- How severe are my symptoms, and how much are they affecting my daily life and sleep?
- What is my personal and family health history (breast cancer, blood clots, heart disease)?
- Am I within the window where HT benefits are most favorable (under 60, within 10 years of menopause)?
- What delivery method and type of progestogen would minimize my risk profile?
- Are there non-hormonal alternatives that might work equally well for my specific symptoms?
There is no universally “right” answer. But a well-informed, individualized conversation — with a provider who has genuine expertise in menopause — can lead you to the approach that best fits your health and your goals.
The Dr. Binno Approach: Evidence-Based, Never One-Size-Fits-All
Dr. Shereen Binno has navigated the full arc of hormone therapy research — from the pre-WHI era through the alarm of the early 2000s to the nuanced, personalized approach that evidence supports today. As a Certified Menopause Practitioner through The Menopause Society and a Board-Certified OB-GYN with 25+ years of experience, she brings both deep clinical knowledge and a commitment to listening to each patient’s individual story.
At Women’s Health Solutions by Dr. Binno, there are no rushed 10-minute appointments driven by insurance quotas. Initial visits run up to 60 minutes — long enough to actually understand your health history, your concerns, and what matters most to you.
Telehealth appointments are available throughout California and Michigan, with in-person visits offered weekly in Carlsbad, CA.
Schedule a menopause consultation with Dr. Binno →
This article is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare provider for personalized guidance about hormone therapy and your individual health situation.